Summary
In this report we describe the design of adriamycin (ADM)-containing liposome preparations aiming at optimization of various pre-established parameters. Regarding liposome composition phosphatidylserine (PS) and phosphatidylglycerol (PG) appear to be suitable negatively charged phospholipids which combined with phosphatidylcholine (PC) and cholesterol (CHOL), confer to liposomes high loading capacity for ADM and reasonable stability in plasma. Intravenous administration of these negatively-charged liposomes resulted in a favorable tissue distribution of ADM in both normal and tumor-bearing mice, characterized by decreased cardiac uptake of drug, and increased and sustained drug levels in the liver. Moreover, enhanced accumulation of drug also occurred in metastatic tumor cells isolated from the liver when ADM was injected in the liposome-associated form. This passive drug targeting resulted in an improved therapeutic efficiency of liposome-associated ADM in a tumor model of liver metastases. Liposome delivery of ADM was also shown to increase significantly its cytoreductive effect on spleen-infiltrating leukemia cells and to maintain the same cytoreductive efficiency on bone marrow residing leukemia cells with an overall favorable effect on survival in the BCL1 leukemia model. The reduction of ADM toxicity by liposome association together with the anti-tumor results indicate that liposomes represent a useful drug-delivery system for the treatment of major neoplastic conditions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Blum, R.H., Carter, S.K., and Agree, K., 1973, A clinical review of bleomycin: a new antineoplastic agent, Cancer, 31:903.
Forssen, E.A., and Tokes, Z.A., 1981, Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity, Proc. Natl. Acad. Sci. U.S.A., 78:1973.
Gabizon, A., Dagan, A., Goren, D., Barenholz, Y., and Fuks, Z., 1982, Liposomes as in-vivo carriers of Adriamycin: reduced cardiac uptake and preserved anti-tumor activity in mice, Cancer Res., 42:4734.
Gabizon, A., Goren, D., Fuks, Z., Barenholz, Y., Dagan, A., and Meshorer, A., 1983, Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers, Cancer Res., 43:4730.
Gabizon, A., Goren, D., Fuks, Z., Meshorer, A., and Barenholz, Y., 1985, Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumor model, Br. J. Cancer, 51:681.
Goormaghtigh, E. and Ruysschaert, J.M., 1984, Anthracycline glycoside membrane interactions, Biochim. Biophys. Acta, 779:271.
Juliano, R.L. and Stamp, D., 1978, Pharmacokinetics of liposome-encapsulated anti-tumor drugs, Biochem. Pharmacol., 27:21.
Kimeiberg, H.K., Tracy, T.F., Biddlecome, S.M., and Bourke, R.S., 1976, The effect of entrapment in liposomes on the in vivo distribution of 3H-methotrexate in a primate, Cancer Res., 36:2949.
Mayhew, E. and Papahadjopoulos, D., 1983, Therapeutic applications of liposomes, in: “Liposomes,” M.J. Ostro, ed., Marcel Dekker, New York.
Mayhew, E., Rustum, Y., and Vail, W.J., 1983, Inhibition of liver metastases of M5076 tumor by liposome-entrapped adriamycin, Cancer Drug. Deliv. 1:43.
Minow, R.A., Benjamin, R.S., Gottlieb, J.A., 1975, Adriamycin (NSC-123127)-cardiomyopathy: an overview with determination of risk factors, Cancer Chemother. Rep., 6:195.
Olson, F., Mayhew, E., Maslow, D., Rustum, Y., and Szoka, F., 1982, Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes, Eur. J. Cancer Clin. Oncol., 18:167.
Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R., and Fidler, I.J., 1982, Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery, Cancer Res., 42: 1412.
Poste, G., 1983, Liposome targeting in vivo: problems and opportunities, Biol. Cell., 47:19.
Rahman, Y., Wright, B.J., 1975, Liposomes containing chelating agents: Cellular penetration and a possible mechanism of metal removal, J. Cell. Biol., 65:112.
Rahman, A., Kessler, A., More, N., Sikic, B., Rowden, G., Woolley, P., and Schein, P.S., 1980, Liposomal protection of adriamycin-induced cardiotoxicity in mice, Cancer Res., 40:1532.
Rosenthal, S. and Kaufman, S., 1974, Vincristine neurotoxicity, Ann. Intern. Med., 80:733.
Segal, A.W., Wills, E.J., Richmond, J.E., Slavin, G., Black, C.D.V., and Gregoriadis, G., 1974, Morphological observations on the cellular and subcellular destination of intravenously administered liposomes, Br. J. Exp. Pathol., 55:320.
Van Hoesel, Q.G.C.M., Steerenberg, P.A., Crommelin, D.J.A., Van Dijk, A., Van Oort, W., Klein, S., Douze, J.M.C., deWildt, D.J., and Hillen, F.C., 1984, Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat, Cancer Res., 44:3698.
Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L., Von Hoff, A.L., Rozencweig, M., and Muggia, F.M., 1979, Risk factors for doxorubicin-induced congestive heart failure, Ann. Intern. Med., 91:710.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Gabizon, A., Goren, D., Ramu, A., Barenholz, Y. (1986). Design, Characterization and Anti-Tumor Activity of Adriamycin-Containing Phospholipid Vesicles. In: Gregoriadis, G., Senior, J., Poste, G. (eds) Targeting of Drugs With Synthetic Systems. NATO ASI Series, vol 113. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5185-6_17
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5185-6_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5187-0
Online ISBN: 978-1-4684-5185-6
eBook Packages: Springer Book Archive